Use of inhaled corticoids as a risk factor for community-acquired pneumonia in patients with chronic obstructive pulmonary disease

Uso de corticoides inhalados como factor de riesgo de neumonía adquirida en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica

Authors

  • María Alejandra Castillo Vega Professional School of Human Medicine, Human Medicine Faculty, Universidad Privada Antenor Orrego, Trujillo-Peru.
  • Gilmar Robert Mejía Sánchez Hospital Victor Lazarte Echegaray

DOI:

https://doi.org/10.25176/RFMH.v23i3.5604

Keywords:

Chronic obstructive pulmonary disease (COPD), corticosteroids, pneumonia

Abstract

Objective: To determine if the use of inhaled corticosteroids is a risk factor for community-acquired pneumonia in patients with Chronic Obstructive Pulmonary Disease at the Víctor Lazarte Echegaray Hospital during the period 2017-2020. Methods: The study was analytical, observational, retrospective of cases and unmatched controls in a ratio of 4:1 with a population of 405 subjects from whom 81 cases and 324 controls were selected, who met the selection criteria. A non-probabilistic sampling was carried out. The variables, use of inhaled corticosteroids, patients with community-acquired pneumonia, age, sex, malnutrition and smoking were included. The association measure was made using Pearson's non-parametric Chi Square test. The bivariate and multivariate analysis was performed using multiple logistic regression with statistical significance (p value <0.05). The study statistician was the Odds ratio (OR). Results: Through the multivariate analysis of the variables under study, no relationship was found between the use of inhaled corticosteroids and patients with community-acquired pneumonia (OR= 1.17; 95%CI: 0.48-2.99 and p value=0.737). It was observed that only age can be considered as a risk factor in view of its significance (OR=1.09; 95%CI: 1.06-1.12 and p value<0.001), while the variables sex, malnutrition, and smoking proved not to be significant ( p> 0.05). Conclusions: The use of inhaled corticosteroids is not a risk factor for community-acquired pneumonia in patients with Chronic Obstructive Pulmonary Disease.

Keywords: Chronic Obstructive Pulmonary Disease (COPD), corticosteroids, pneumonia. (source: MeSH NLM)

Downloads

Download data is not yet available.

Author Biographies

María Alejandra Castillo Vega, Professional School of Human Medicine, Human Medicine Faculty, Universidad Privada Antenor Orrego, Trujillo-Peru.

Medical doctor

Gilmar Robert Mejía Sánchez, Hospital Victor Lazarte Echegaray

Medical doctor specialized in Pulmonology

References

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. [Internet] Global strategy for the diagnosis, management and prevention of COPD. [consultado el 20 de octubre del 2019] Disponible en: www.goldcopd.org.

Organización Mundial de la Salud 2014. [Internet]. Organización Mundial de la Salud en línea. [consultado el 20 de octubre de 2019]. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

Miravitlles M, Soler-Cataluña J, Calle M, Molina J, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Archivos de Bronconeumología. [Internet]. 2017 [citado el 20 de octubre de 2019]; 53(6):324-335. doi: 10.1016/j.arbres.2017.03.018

Morros R, Vedia C, Giner-Soriano M, Casellas A, et al. Neumonías adquiridas en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica tratados con corticoides inhalados u otros broncodilatadores. Estudio PNEUMOCORT. Atención Primaria. [Internet]. 2019 [citado el 20 de octubre de 2019]; 51(6):333-340. doi: 10.1016/j.aprim.2018.02.007

Díaz A, Undurraga P. Uso y abuso de los corticoides en las enfermedades respiratorias. Revista Chilena de Enfermedades Respiratorias. [Internet] 2013 [citado el 22 de octubre de 2019]; 29(2):67-69. Disponible en: https://revchilenfermrespir.cl/index.php/RChER/article/view/359

Yawn B, Li Y, Tian H, Zhang J, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. International Journal of COPD. [Internet] 2013 [citado el 22 de octubre de 2019]; 8:295-304. doi: 10.2147/COPD.S42366

Joo M, Au D, Fitzgibbon M, Lee T. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respiratory Medicine. [Internet] 2010 [citado el 22 de octubre de 2019]; 104(2):246-252. doi: 10.1016/j.rmed.2009.10.002

Morjaria J, Rigby A, Morice A. Inhaled corticosteroid use and the risk of pneumonia and COPD exacerbations in the UPLIFT study. Lung. [Internet] 2017 [citado el 22 de octubre de 2019]; 195(3):281-8. doi: 10.1007/s00408-017-9990-8

Lee M-C, Lee C-H, Chien S-C, Chang J-H, She H-L, Wang J-Y, et al. Inhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: A nationwide cohort study. Medicine. [Internet] 2015 [citado el 22 de octubre de 2019]; 94(42): e1723. doi: 10.1097/MD.0000000000001723

DiSantostefano R, Sampson T, Le H, Hinds D, Davis K, et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: A new-user cohort study. Plos One. [Internet] 2014 [citado el 23 de octubre de 2019]; 9(5): e97149. doi: 10.1371/journal.pone.0097149

Sonnappa S, Martin R, Israel E, Postma D, van Aalderen W, Burden A, et al. Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids. Plos One. [Internet] 2017 [citado el 23 de octubre de 2019]; 12(6): e0178112. doi: 10.1371/journal.pone.0178112

Wang C, Lai C, Yang W, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study. International Journal of Chronic Obstructive Pulmonary Disease. [Internet] 2016 [citado el 30 de octubre de 2019]; 11:2775-2783. doi: 10.2147/COPD.S116750

Declaración de Helsinki de la Asociación Médica Mundial. Adoptada por la 18 Asamblea Médica Mundial, Helsinki, Finlandia, junio de 1964 y enmendada por la 29 Asamblea Médica Mundial, Tokio, Japón, octubre de 1975, la 35 Asamblea Médica Mundial, Venecia, Italia, octubre de 1983 y la 41 Asamblea Médica Mundial, Hong Kong, septiembre de 2011.

Almagro P, Martinez-Camblor P, Soriano JB. Inhaled corticosteroids and pneumonia mortality in COPD patients. European Respiratory Journal. [Internet] 2019 [citado el 9 de agosto de 2021]; 54: 1901035. doi: 10.1183/13993003.01035-2019

Crim C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal [Internet] 2009 [citado el 9 de agosto de 2021]; 34(3): 641–647. doi: 10.1183/09031936.00193908

Lee JH, Park YH, Kang DR, Lee SJ, Lee MK, Kim SH, Yong SJ, Lee WY. Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study. International Journal of Chronic Obstructive Pulmonary Disease. [Internet] 2020 [citado el 9 de agosto de 2021]; 15:3397-3406. doi: 10.2147/COPD.S286149

Chen H, Sun J, Huang Q, Liu Y, Yuan M, Ma C, Yan H. Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials. Front Pharmacol. [Internet] 2021 [citado el 13 de junio de 2023]; 12:691621. doi: doi.org/10.3389/fphar.2021.691621

Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, Wedzicha JA. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respiratory Medicine. [Internet] 2012 [citado el 10 de agosto de 2021]; 106(8):1124-33. doi: 10.1016/j.rmed.2012.04.008

Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Annals of the American Thoracic Society. [Internet] 2015;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC

Lin SH, Perng DW, Chen CP, Chai WH, Yeh CS, Kor CT, Cheng SL, Chen JJ, Lin CH. Increased risk of community-acquired pneumonia in COPD patients with comorbid cardiovascular disease. International Journal of Chronic Obstructive Pulmonary Disease. [Internet] 2016 [citado el 10 de agosto de 2021]; 11:3051-3058. doi: https://doi.org/10.2147/COPD.S115137

Jain NK, Thakkar MS, Jain N, Rohan KA, Sharma M. Chronic obstructive pulmonary disease: Does gender really matter? Lung India. [Internet] 2011 [citado el 10 de agosto de 2021]; 28(4):258-62. doi: 10.4103/0970-2113.85686

Braeken DC, Rohde GG, Franssen FM, Driessen JH, van Staa TP, Souverein PC, Wouters EF, de Vries F. Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom. International Journal of Chronic Obstructive Pulmonary Disease. [Internet] 2017 [citado el 10 de agosto de 2021]; 12:2425-2432. doi: 10.2147/COPD.S138435

Published

2023-09-14 — Updated on 2023-12-06

How to Cite

Castillo Vega, M. A., & Mejía Sánchez, G. R. (2023). Use of inhaled corticoids as a risk factor for community-acquired pneumonia in patients with chronic obstructive pulmonary disease: Uso de corticoides inhalados como factor de riesgo de neumonía adquirida en la comunidad en pacientes con enfermedad pulmonar obstructiva crónica. Revista De La Facultad De Medicina Humana, 23(3), 15–21. https://doi.org/10.25176/RFMH.v23i3.5604

Similar Articles

You may also start an advanced similarity search for this article.